Is BMY stock a Buy, Sell, or Hold?

Based on our analysis, BMY is currently a HOLD with moderate confidence. 📊 HOLD: BMY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of BMY stock?

Our analysis estimates the fair value range for BMY to be between $56.85 and $59.35. The current price is $56.49.

What is the analyst price target for BMY?

The average Wall Street analyst price target for BMY is $63.32. This implies a potential upside of 12.3% from current levels.

BMY Stock Analysis: Buy, Sell, or Hold?

BMY - Bristol-Myers Squibb Co.

PHARMACEUTICAL PREPARATIONS

$56.50

0.10 (0.19%) ▲

5d: +0.44%

30d: -2.41%

90d: -5.62%

HOLD

MODERATE Confidence

Protect Your BMY Gains

Analysis Updated: May 13, 2026 12:00 AM ET

Earnings: Apr 30, 2026 0d

Smart Money Accumulation

BMY is down 3.2% this week, but smart money is accumulating calls. Top strike: $62.5 2026-06-18 with 42,634 OI. Call ratio: 73% View Scanner →

Strength: 3.9/10

Get Alerted When BMY Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: BMY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: -2.5%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$59.91

Based on 0.8% avg growth

INTRINSIC VALUE TODAY

$37.20

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: BMY is currently trading at $56.49, which is considered oversold relative to its 30-day fair value range of $56.85 to $59.35. The stock's valuation (Forward PE: 9.2) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 9.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, BMY is in a uptrend. The price is currently testing key support at $55.41. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: BMY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $63.32 (+12.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $56.85 - $59.35

Company Quality Score 56/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 54.8%

Protect Your Profits

Holding BMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($63.32)

Trading Range Analysis

30-Day Trading Range $56.85 - $59.35

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $55.41

Resistance Level $60.09

Current Trend Uptrend

Technical data as of May 14, 2026

Fundamental Context

Forward P/E (Next Year Est.) 9.17

Wall Street Target $63.32 (+12.3%)

Revenue Growth (YoY) 2.6%

Earnings Growth (YoY) 9.2%

Profit Margin 15.0%

Valuation Discount vs History -0.8% cheaper

PE vs Historical 9.2 vs 9.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -0.8% (market-implied from PE analysis)

1-Year Target $55.94 (-1%)

2-Year Target $55.49 (-2%)

3-Year Target $55.05 (-2%)

3-Yr Target (if PE normalizes) (PE: 9→9) $56.41 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 22.0, Growth: -2.5%) $125.68 (+123%)

Base: (SPY PE: 9.2, Growth: -2.5%) $52.31 (-7%)

Bear: (PE: 7.8, Growth: -2.5%) $44.46 (-21%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (9x PE) as earnings recover.

Trailing PE: 15.73 | Current EPS (TTM): $3.54

Bull Case $106.34 (+89%)

Analyst growth 73.7%, PE expands to 17.3

Base Case $96.67 (+71%)

Market implied 73.7%, PE stable at 15.7

Bear Case $37.86 (-33%)

Severe decline -20.0%, PE contracts to 13.4

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 9.2 to 9.4

Stabilization Target: $57.78 (+2.5%)

PE Expansion Potential: +2.5%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: May 14, 2026 11:32 AM ET
Data refreshes hourly during market hours. Next update: 12:32 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is BMY showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

David V Elkins SELL 30000 shares 2026-04-01

Ro Khanna BUY 2026-02-05

Ro Khanna SELL 2026-01-29

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for BMY.

Create Free Account

Already have an account? Log In

Featured in Portfolios

BMY is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • -0.4% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 29 analysts	$1209	61 BUY
GILD Gilead Sciences Inc	BUY 30 analysts	$158	59 HOLD
ABBV AbbVie Inc	BUY 28 analysts	$252	63 BUY
BIIB Biogen Inc	HOLD 37 analysts	$217	64 BUY
AMGN Amgen Inc	HOLD 32 analysts	$353	58 HOLD

LLY Eli Lilly and Com…

61 BUY

GILD Gilead Sciences I…

Advanced BMY Option Strategies

Professional options setups generated by AI based on today's BMY price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for BMY

BMY Technical Chart BMY Price Prediction BMY Earnings Date BMY Investment Advisor BMY Fair Price Analyzer BMY Options Advisor BMY Options Chain BMY Options Analysis BMY Competitors

Compare BMY with Peers

BMY vs MRK
Which one to buy?

BMY vs ABT
Which one to buy?

BMY vs LLY
Which one to buy?

BMY vs ABBV
Which one to buy?

BMY vs AMGN
Which one to buy?

CPHI vs BMY
Winner: BMY

ABBV vs BMY
Winner: BMY

Create New Comparison View All Competitors

Tradestie